GlassScriptPhysician profile
Elida O Drew
NPI 1457947236
$2,021.98
in general payments reported to CMS, 2019-2025
27 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $453 · 2023: $918 · 2024: $531 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,569.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $474.23 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $161.47 | 2023-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $161.21 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $125.12 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $120.15 | 2025 | Voquezna |
| Dexcom, INC. | $119.00 | 2023 | Dexcom G7 Gss (161) |
| Abbvie INC. | $106.93 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $104.64 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $98.57 | 2022-2023 | Farxiga |
| Axsome Therapeutics, INC. | $98.30 | 2024 | Auvelity |
| Cardiovascular Systems INC. | $83.93 | 2022-2023 | Diamondback Peripheral |
| Astellas Pharma US INC | $48.73 | 2024 | Veozah |
| Corium, LLC | $37.55 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $36.80 | 2023 | Rexulti |
| Exact Sciences Corporation | $29.70 | 2023-2024 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.34 | 2023 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $24.02 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $22.84 | 2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $18.72 | 2023 | Xarelto |
| Vanda Pharmaceuticals INC. | $18.44 | 2023 | Hetlioz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.44 | 2024 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $18.26 | 2024 | Gvoke Hypopen |
| Tris Pharma INC | $17.35 | 2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $14.84 | 2023 | Quviviq |
| Tolmar, INC. | $13.40 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $12.13 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elida Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.